河北省脊髓灰质炎疫苗疑似预防接种异常反应监测分析

发布时间：2018-05-27 17:12

  本文选题：脊髓灰质炎减毒活疫苗 + 脊髓灰质炎灭活疫苗　； 参考：《中国疫苗和免疫》2017年05期

【摘要】：目的比较分析河北省脊髓灰质炎(脊灰)疫苗预防接种的安全性。方法收集河北省2015年5-10月三价脊灰减毒活疫苗(tOPV)、脊灰灭活疫苗(IPV)和2016年同期二价脊灰减毒活疫苗(bOPV)、IPV的疑似预防接种异常反应(AEFI)监测数据,比较分析各疫苗AEFI报告发生率。结果河北省2015年5-10月tOPV、IPV的AEFI报告发生率分别为5.64/10万、35.96/10万;2016年同期bOPV、IPV的AEFI报告发生率分别为16.06/10万、17.85/10万。各疫苗AEFI均以≤1岁年龄组、一般反应为主,主要发生在接种疫苗后≤48h。结论河北省各脊灰疫苗预防接种安全性良好,bOPV的AEFI报告发生率高于tOPV,需进一步加强脊灰疫苗安全性监测。
[Abstract]:Objective to compare and analyze the safety of polio vaccination in Hebei province. Methods the surveillance data of suspected abnormal vaccination response (AEFIe) of live attenuated poliomyelitis vaccine (AEFI) in Hebei province from May to October 2015 and bivalent live attenuated polio vaccine from 2016 were collected, and the reported incidence of AEFI was compared and analyzed. Results from May to October 2015, the incidence of AEFI reporting of tOPV-IPV in Hebei Province was 564 / 100 000 or 359.6 / 100 000, respectively, and the incidence rate of AEFI reporting of AEFI in the same period of 2016 was 16.06 / 100 000 or 17.85% / 100 000 respectively. The AEFI of each vaccine was mainly in the age group of 鈮，

本文编号：1943070